Please click here to receive a FREE SCOLIOSIS TREATMENT INFORMATION KIT ASAP.

 

On March 15th, 2010, the SCOLISCORE™ AIS Prognostic Test became the spine industry’s first prognostic test designed to utilize validated genetic markers to assess the likelihood of AIS curve progression. With the launch of this promising new technology, the responsibility to provide peer-reviewed, evidence based publications to the scientific community, which support the clinical validity and high predictive accuracy of the SCOLISCORE Test, is of paramount importance to both DePuy Spine and Axial Biotech. With this in mind, it is with great excitement that we inform you that the journal, SPINE, has just published on-line, a landmark paper on Prognostic Genetic Testing for AIS, featuring the SCOLISCORE Test.

http://journals.lww.com/spinejournal...urrenttoc.aspx landmark paper represents years of research by world-renowned geneticists and spine surgeons, in classifying the genetic markers that predict which minor AIS curves are not likely to progress to a severe curve. Clinical use since launch of the SCOLISCORE Test has demonstrated that the knowledge of a patient’s genetic predisposition to curve progression, when combined with existing radiographic and clinical information, has empowered physicians and families to make more informed, personalized, clinically actionable patient care decisions.

This

This is an exciting time in the treatment of complex spinal deformity. While the introduction of the SCOLISCORE Test and the recent SPINE publication are important steps toward the advancement of care of spine patients, our organizations remain committed to working with thought-leading physicians to continue to develop transformational technologies which improve the standard of care for patients with debilitating conditions of the spine.

We encourage you to take a moment to download this pivotal paper to learn more about the clinical validation trials behind the highly predictive and accurate SCOLISCORE Test.